Medtronic (NYSE:MDT) Stock Gets Downgrade from Wall Street Zen

Medtronic (NYSE:MDT – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Monday, Wall Street Zen reports.

Several other research firms have also commented on MDT. BTIG Research dropped their price target on shares of Medtronic from $100.00 to $99.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Barclays upgraded shares of Medtronic to a “hold” rating in a research report on Wednesday, October 7th. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Wednesday, October 14th. Weiss Ratings upgraded Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 19th. Finally, Needham & Company LLC restated a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Nineteen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $104.28.

Get Our Latest Research Report on MDT

Medtronic Trading Down 0.6%

Medtronic stock opened at $102.24 on Monday. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33. The stock’s 50 day simple moving average is $94.09 and its two-hundred day simple moving average is $88.49. The firm has a market cap of $130.78 billion, a PE ratio of 17.99, a P/E/G ratio of 2.41 and a beta of 0.56.

Medtronic (NYSE:MDT – Get Free Report) last posted its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same period in the previous year, the firm earned $1.26 EPS. The business’s quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Analysts anticipate that Medtronic will post 5.98 earnings per share for the current year.

Insider Activity at Medtronic

In other Medtronic news, CEO Geoffrey Martha sold 50,000 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the transaction, the chief executive officer directly owned 277,866 shares in the company, valued at approximately $26,397,270. This represents a 15.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the transaction, the executive vice president directly owned 42,186 shares in the company, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is owned by company insiders.

Institutional Trading of Medtronic

A number of institutional investors and hedge funds have recently modified their holdings of MDT. BlackRock Inc. grew its position in Medtronic by 0.7% in the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after buying an additional 838,220 shares during the last quarter. State Street Corp increased its stake in Medtronic by 4.1% in the 3rd quarter. State Street Corp now owns 65,987,354 shares of the medical technology company’s stock valued at $5,741,306,000 after buying an additional 2,588,039 shares during the period. Bank of America Corp DE raised its position in Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after buying an additional 1,343,220 shares during the last quarter. First Eagle Investment Management LLC raised its position in Medtronic by 1.2% during the 3rd quarter. First Eagle Investment Management LLC now owns 13,948,408 shares of the medical technology company’s stock worth $1,203,608,000 after buying an additional 164,425 shares during the last quarter. Finally, WCM Investment Management LLC purchased a new position in Medtronic during the 1st quarter worth $965,922,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Key Medtronic News

Here’s some of the latest news about MDT:

  • Positive Sentiment: The FDA cleared Medtronic’s Hugo robotic-assisted surgery system for general surgery in the U.S. The expanded authorization opens access to an estimated 3.5 million annual U.S. cases and procedures that represent more than half of U.S. soft-tissue surgeries, increasing Hugo’s commercial opportunity. Article: Medtronic’s Hugo robot gets expanded FDA clearance in general surgery
  • Positive Sentiment: Medtronic plans to acquire Contego Medical for $380 million, adding carotid and peripheral vascular technologies to its portfolio. The deal builds on an existing U.S. distribution relationship and could strengthen its vascular-intervention business. Article: Medtronic to buy Contego Medical for $380M
  • Neutral Sentiment: A preview of Medtronic’s Q2 results points to Cardiovascular momentum, particularly cardiac ablation, with Neuroscience and Diabetes also expected to contribute growth. These are expectations ahead of the earnings report, not reported results. Article: MDT Q2 Earnings Preview

About Medtronic

(Get Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Further Reading

Analyst Recommendations for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.